NDA 214952, held by Cmp Dev LLC. Sildenafil Citrate.
As of Nov 13, 2026, NDA 214952 (Liqrev), held by Cmp Dev LLC, was first approved by FDA on Apr 28, 2023, with 0 approved supplements and 2 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 28, 2023 | Original applicationNew formulation or manufacturer · Standard review | Approved |
| Apr 28, 2022 | SildenafilFacility Inspections | Approved |
| Aug 5, 2021 | LIQREV (sildenafil)Product Quality | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| LiqrevEQ 10MG BASE/ML · suspension;oral | Sildenafil Citrate | DiscontinuedReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
